Post-translational modification of p53 in tumorigenesis
By Ann M. Bode, Zigang Dong. Nature Reviews. Cancer, 2004
1,315 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/804f91eef973473eb074c6b66cfde07e533383e1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
- Karen H. Vousden
- Carol Prives
- F. Toledo
- M. Hollstein
- G. Wahl
- S. Minucci
- Pier Giuseppe Pelicci
- Vladimir N Uversky
In Oncology
- Carol Prives
- Karen H. Vousden
- M. Hollstein
- S. Minucci
- Pier Giuseppe Pelicci
- Bin Liu
- D. Meek
- Vladimir N Uversky
Citations in the corpus
- The Tumor Suppressor Protein p53 and the Ferroptosis Network (2018, neutral): “These context-dependent roles of p53 in survival and death are regulated in a fine-tuned manner by its ubiquitination, phosphorylation, acetylation, and other modifications [9,10].”
- Regulating the p53 pathway: in vitro hypotheses, in vivo veritas (2006, background): “Many of these modifications were recently reviewed in this journa”
- ROS and p53: a versatile partnership. (2008, background): “The stability and activity of p53 are subject to diverse covalent post-translational modifications such as ubiquitylation [66], phosphorylation [67], acetylation [68], neddylation [69], sumoylation [70], and methylation [71].”
- Blinded by the Light: The Growing Complexity of p53. (2009, background): “As there are a number of excellent reviews covering these aspects of p53 regulation (Appella and Anderson, 2001; Bode and Dong, 2004; Kruse and Gu, 2008; Olsson et al., 2007), we will focus on discussing findings relevant to a few key p53 modifications that selectively impact the cellular outcomes…”
- p53 polymorphisms: cancer implications (2009, background): “Numerous stress sensors that converge at p53 result in the phosphorylation, acetylation, ubiquitylation and methylation of specific p53 residue”
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (2006, background): “The oncosuppressor p53 is regulated by acetyl-ation, which regulates the stability of the protein, its interaction with DNA and its transcriptional activit”